Pharmacodynamic Properties of Subcutaneous Immunoglobulin in Myasthenia Gravis: Sub-analyses From an Open-Label Trial

Background: We previously reported an open-label prospective trial of subcutaneous immunoglobulin (SCIg) in mild to moderate exacerbations of myasthenia gravis (MG). The effective dose of SCIg in MG and whether measured immunoglobulin G (IgG) levels correlated with measures of disease burden were no...

Descripción completa

Detalles Bibliográficos
Autores principales: Putko, Brendan N., Beecher, Grayson, Siddiqi, Zaeem A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477386/
https://www.ncbi.nlm.nih.gov/pubmed/32982936
http://dx.doi.org/10.3389/fneur.2020.00921

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7477386/
https://www.ncbi.nlm.nih.gov/pubmed/32982936
http://dx.doi.org/10.3389/fneur.2020.00921

Ejemplares similares